
Hantavax ($HANTAVAX) bridges decentralized finance with frontline medical research to engineer the world's first definitive vaccine against the Andes Orthohantavirus strain.
Price
$0.0000421
Market Cap
$4.2M
Liquidity
🔒 Locked
The Crisis
The Andes Orthohantavirus is the only hantavirus strain confirmed to transmit person-to-person. With fatality rates exceeding 35%, and zero commercially available vaccines in Western markets, the global window for intervention is narrowing. Hantavax exists to close that gap.
35% – 40%
Average Fatality Rate of Hantavirus Pulmonary Syndrome
0 Approved
Vaccines commercially available in Western markets for the Andes strain
100% Dedicated
Smart contract allocation directed to medical research grants and vaccine pipelines
How It Works
Every transaction fuels the mission. A transparent, immutable pipeline from market activity to medical breakthroughs.
Community buys and trades $HANTAVAX tokens on decentralized exchanges, building liquidity and grassroots funding momentum.
Automated transaction fee mechanisms safely divert designated percentages into a multi-signature Medical Ecosystem Fund.
Capital is deployed directly to independent virology laboratories and clinical research teams globally to bridge funding gaps.
Documentation
Sections
ANDV belongs to family Hantaviridae, the only hantavirus with person-to-person transmission.
Viral glycoproteins Gn/Gc mediate host-cell attachment. Primary antigenic targets for vaccine design.
Andes virus spreads via respiratory droplets between humans, unlike other rodent-borne hantaviruses.
Roadmap
A phased approach modeled after clinical trial methodology.